News

Ozempic and Mounjaro have new competitor as trial sees people lose 20% of bodyweight in one year
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
STAT18h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Devdiscourse15h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
Results From Amgen's Phase 2 Obesity Study Of Monthly Maritide Presented At The American Diabetes Association 85th Scientific Sessions
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...
Healio15h
Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...